Browsing Tag

VERU111

Veru Announces the Presentation of a Phase 1b/2 Clinical Study Update for Sabizabulin (VERU-111) in…

Jason Junior Jun 28, 2021

MIAMI, June 28, 2021 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate and breast cancers, today announced updated clinical…

Health

Veru Enrolls First Patient in Phase 3 VERACITY Clinical Trial of Sabizabulin (VERU-111) in…

Jason Junior Jun 26, 2021

--Sabizabulin is a novel oral androgen receptor transport disruptor---- In Phase 1b/2 clinical study, sabizabulin was well tolerated with significant antitumor efficacy in metastatic castration resistant prostate cancer patients who have…

Health

Veru Enrolls First Patient in Phase 3 Clinical Trial of Sabizabulin (VERU-111) in High Risk…

Jason Junior May 19, 2021

—Sabizabulin is a novel oral agent with both anti-viral and anti-inflammatory activities— —Sabizabulin treatment reduced mortality in hospitalized COVID-19 patients at high risk for Acute Respiratory Distress Syndrome in Phase 2 study—…